/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Neurocrine Biosciences Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$151.65 -0.0034(-0.34%) NBIX at 04 Dec 2025 04:39 PM Drug Manufacturers - Specialty & Generic
Lowest Today 150.26
Highest Today 154.34
Today’s Open 153.25
Prev. Close 152.48
52 Week High 157.67
52 Week Low 84.23
Day’s Range: Low 150.26 High 154.34
52-Week Range: Low 84.23 High 157.67
1 day return -
1 Week return -0.15
1 month return +6.04
3 month return +8.12
6 month return +21.86
1 year return +18.79
3 year return +22.43
5 year return +57.32
10 year return -

Institutional Holdings

BlackRock Inc 13.06

Vanguard Group Inc 9.89

Dodge & Cox 5.61

State Street Corp 4.51

JPMorgan Chase & Co 4.30

Dodge & Cox Stock I 4.00

iShares Core S&P Mid-Cap ETF 3.25

Vanguard Total Stock Mkt Idx Inv 3.14

T. Rowe Price Associates, Inc. 3.11

Vanguard Small Cap Index 2.42

Renaissance Technologies Corp 2.39

Citadel Advisors Llc 2.07

Wellington Management Company LLP 2.05

Geode Capital Management, LLC 1.98

BB Biotech AG Ord 1.84

Bellevue Group AG 1.84

Morgan Stanley - Brokerage Accounts 1.83

AQR Capital Management LLC 1.52

UBS Asset Mgmt Americas Inc 1.40

Vanguard Small Cap Growth Index Inv 1.36

Millennium Management LLC 1.20

Deerfield Management Co 1.18

BRAIDWELL LP 1.17

Vanguard Windsor Investor Shares 1.14

JPM US Mid Cap Growth-Composite 1.12

JPMorgan Mid Cap Growth I 1.12

T. Rowe Price US Mid-Cap Value Equity 1.07

Vanguard Institutional Extnd Mkt Idx Tr 1.07

T. Rowe Price Mid-Cap Value 1.07

RTW INVESTMENTS, LLC 1.07

BNP Paribas Investment Partners SA 1.04

NORGES BANK 0.98

SPDR® S&P Biotech ETF 0.95

JPMorgan Growth Advantage A 0.93

SPDR® S&P MIDCAP 400 ETF Trust 0.76

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D 0.58

iShares Biotechnology ETF 0.57

iShares S&P Mid-Cap 400 Growth ETF 0.57

T. Rowe Price Health Sciences 0.57

iShares MSCI USA Min Vol Factor ETF 0.56

Market Status

Strong Buy: 15

Buy: 7

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15203.12 M

PB Ratio 5.0095

PE Ratio 36.3048

Enterprise Value 14360.19 M

Total Assets 3718.70 M

Volume 823304

Company Financials

Annual Revenue FY24:2355300000 2355.3M, FY23:1783900000 1783.9M, FY22:1488700000 1488.7M, FY21:1133500000 1133.5M, FY20:1045900000 1045.9M

Annual Profit FY24:2321300000 2321.3M, FY23:1745000000 1745.0M, FY22:1465500000 1465.5M, FY21:1119200000 1119.2M, FY20:1035800000 1035.8M

Annual Net worth FY24:341300000 341.3M, FY23:191000000 191.0M, FY22:154500000 154.5M, FY21:89600000 89.6M, FY20:407300000 407.3M

Quarterly Revenue Q3/2025:794900000 794.9M, Q2/2025:687500000 687.5M, Q1/2025:572600000 572.6M, Q4/2024:627700000 627.7M, Q3/2024:622100000 622.1M

Quarterly Profit Q3/2025:780900000 780.9M, Q2/2025:676200000 676.2M, Q1/2025:563400000 563.4M, Q4/2024:618400000 618.4M, Q3/2024:614100000 614.1M

Quarterly Net worth Q3/2025:209500000 209.5M, Q2/2025:107500000 107.5M, Q1/2025:7900000 7.9M, Q4/2024:103100000 103.1M, Q3/2024:129800000 129.8M

Fund house & investment objective

Company Information Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Organisation Drug Manufacturers - Specialty & Generic

Employees 1800

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Kyle W. Gano Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow